Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753154 | 1.00 | CA12 (0.52) | CA12CA1CA9CA2CA7 | |
| SCHEMBL20809519 | 0.83 | PYGL (0.47) | CA12CA1CA9NPY1RSIRT2 | |
| SCHEMBL31752513 | 0.82 | CA12 (0.59) | CA12CA1CA9CA2CA7 | |
| SCHEMBL13653136 | 0.81 | CA12 (0.45) | CA12CA1CA9CA2CA7 | |
| SCHEMBL14902975 | 0.81 | CA12 (0.45) | CA12CA1CA9CA2CA7 | |
| SCHEMBL31730541 | 0.80 | NPY1R (0.50) | CA1CA2NPY1RRAB9ANPC1 | |
| SCHEMBL31055934 | 0.80 | NPY1R (0.50) | CA1CA2NPY1RRAB9ANPC1 | |
| SCHEMBL15199648 | 0.80 | CA12 (0.43) | CA12CA1CA9NPY1RSIRT2 | |
| SCHEMBL31056014 | 0.79 | MGLL (0.51) | CA12CA1CA9CA2CA7 | |
| SCHEMBL24817021 | 0.78 | TRPV1 (0.47) | CA12CA1CA9CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025034613-A1 | 3H-IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | CA12 1769/4885CA1 1957/4885CA9 1752/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | CA12 2747/4885CA1 2242/4885CA9 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.